|
Sector |
Healthcare |
|
Initial Investment Date |
IPGL invested in November 2003 |
|
Investment Stage |
Post-IPO |
|
Role |
Activist investor |
|
Description |
Cyprotex is a specialist out-source provider of in-vitro and in-silico assessment of Absorption, Distribution, Metabolism, Elimination and Toxicity (ADMET) properties of potential drugs. It has over 170 pharmaceutical and biotech clients. The company is quoted on AIM (code: CRX). Chris Clothier is the Investment Director currently managing the investment in Cyprotex for IPGL. |
|
Website |
